VB - Vanguard Small-Cap ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
161.64
+0.88 (+0.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close160.76
Open160.53
Bid0.00 x 900
Ask0.00 x 800
Day's Range160.26 - 161.73
52 Week Range131.26 - 161.74
Volume438,250
Avg. Volume602,579
Net Assets92.97B
NAV158.56
PE Ratio (TTM)N/A
Yield1.35%
YTD Return7.83%
Beta (3y)1.02
Expense Ratio (net)0.05%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • Investopedia2 months ago

    Top 3 Small-Cap ETFs for 2018

    There's a case to be made that small-cap ETFs will outperform in the months ahead. Here are a few to consider.

  • How to Invest with Confidence
    Zacks6 months ago

    How to Invest with Confidence

    Did the recent stock market correction give you jitters? You're not alone. Find out how to take charge of your investing.

  • ETF Trends6 months ago

    Rising Interest Rates Does Not Spell Doom for Stock ETFs

    The Federal Reserve typically hikes interest rates to obviate an overheating economy during the later stages of an economic cycle, typically foreshadowing the eventual end of a bull market. Nevertheless, ...

  • Taking Stock of Globus Medical’s Recent Acquisitions
    Market Realist6 months ago

    Taking Stock of Globus Medical’s Recent Acquisitions

    Globus Medical (GMED) recently launched a robotic surgical navigation device. Since its inception in 2003, Globus Medical has launched more than 180 products. Globus Medical acquired KB Medical, a Switzerland-based robotic developer, in June 2017.

  • Investopedia7 months ago

    Top 3 Small-Cap ETFs for 2018

    There's a case to be made that small-cap ETFs will outperform in the months ahead. Here are a few to consider.

  • A Deeper Look at Nektar Therapeutics’ Licensing Agreements
    Market Realist7 months ago

    A Deeper Look at Nektar Therapeutics’ Licensing Agreements

    Nektar Therapeutics (NKTR) has entered into a number of licensing and collaboration agreements for research, development, and commercialization with various healthcare companies, including Eli Lilly (LLY), AstraZeneca (AZN), and Amgen (AMGN). Under these agreements, Nektar is entitled to receive license fees, milestone payments, royalties, and payments for manufacturing and supplying Nektar’s proprietary PEGylation materials.

  • Investopedia9 months ago

    Top 3 Small-Cap ETFs for 2017

    There's a case to be made that small-cap ETFs will outperform in the final months of 2017. Here are a few to consider.

  • 5 Small-Cap ETFs That Knock Out the Competition
    InvestorPlace9 months ago

    5 Small-Cap ETFs That Knock Out the Competition

    When it comes to investing, small-cap stocks beat large caps as the best ETFs to buy. After all, it’ll take a lot of a behemoth like International Business Machines Corp. (NYSE:IBM) to get the ship moving. Which is why small-cap stocks have tacked on an extra 253% in cumulative extra returns over large-cap stocks.

  • The 3 Best Vanguard ETFs to Get Your ‘Risk On’
    InvestorPlace9 months ago

    The 3 Best Vanguard ETFs to Get Your ‘Risk On’

    While risk-takers will eschew broader-scoped exchange-traded funds (ETFs) for the glory (and profits) of individual stocks, ETFs are a relevant component of any investing strategy. While the profit potential is greatest with a bet on a single company, the opposite is also true. Over the long run, the law of averages makes choosing the best Vanguard ETFs particularly compelling.

  • Stocks Mixed As Biotechs Dive; Buffett Stocks Near Buy Point?
    Investor's Business Daily10 months ago

    Stocks Mixed As Biotechs Dive; Buffett Stocks Near Buy Point?

    Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.

  • Dow Sells Off As Boeing, GE Weigh; Chance To Buy Small Caps?
    Investor's Business Daily10 months ago

    Dow Sells Off As Boeing, GE Weigh; Chance To Buy Small Caps?

    Key U.S. stock indexes sold off Wednesday as earnings reports continued and amid renewed talk about changes to 401(k) contribution limits.

  • PowerShares Launches Small-Cap Equity ETF
    Zacks10 months ago

    PowerShares Launches Small-Cap Equity ETF

    PowerShares rolls out small-cap U.S. equity ETF.

  • Hot Areas of Last Week and Their ETFs
    Zacks11 months ago

    Hot Areas of Last Week and Their ETFs

    Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.

  • Market Realist11 months ago

    Nuplazid Sees Increasing Physician Intent to Prescribe in 2017

    Acadia Pharmaceuticals' (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.

  • Morningstarlast year

    Small Caps: The Easy Game for Active Managers?

    The odds may be better for small-cap managers, but they're still long.

  • Here's Why Small Cap ETFs Are Underperforming
    Zackslast year

    Here's Why Small Cap ETFs Are Underperforming

    U.S. small cap ETFs suffer on account of growing uncertainty around Trump's pro-growth policies.